Drugs / PeproStat
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02204930 | Jul 2014 → Sep 2015 | hemorrhagic disease | Haemostatix Ltd | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03131336 | Mar → Aug 2017 | hemorrhagic disease | Haemostatix Ltd | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PeproStat | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02204930 ↗ |
| Modality | Peptide | “PeproStat, a new peptide based coagulant (haemostat)” NCT02204930 ↗ |
| Route | Topical | “PeproStat is formulated in a liquid, and is soaked into a haemostatic gelatin sponge in the operating theatre, and applied directly to the site of bleeding.” NCT03131336 ↗ |